Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.
BLCM has three product candidates in clinical development: BPX-501, an adjunct T-cell therapy product candidate being evaluated in Phase I/II clinical trials in children and adults following a T-depleted, haploidentical hematopoietic stem cell transplant (HSCT); BPX-601, a GoCAR-T product candidate in Phase I development for solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate in Phase I development for AML with future development potential for treatment of solid tumors expressing the preferentially-expressed antigen in melanoma.
BLCM has collaboration agreements with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesú for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens.
Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
March 26, 2024
RegMed Investors (RMi) Closing Bell: a negative sector close
March 25, 2024
RegMed Investors (RMi) Closing Bell: twists and turns as Monday closes barely positive and a coming end of March and Q1/24
March 22, 2024
RegMed Investors (RMi) Closing Bell: A question had been asked, are there legs to the sector?
March 21, 2024
RegMed Investors (RMi) Closing Bell: The cell and gene therapy sector faltered
March 19, 2024
RegMed Investors (RMi) Closing Bell: Short-volatility based trades or actual sentiment shaping?
March 18, 2024
RegMed Investors (RMi) Closing Bell: a session of cell and gene therapy sector shifting share pricing
March 15, 2024
RegMed Investors (RMi) Closing Bell: triple witching Friday
March 13, 2024
RegMed Investors (RMi) Closing Bell: drop and give me push-ups, I’ll count until the PPI and jobless claims numbers order
March 12, 2024
RegMed Investors (RMi) Closing Bell: fresh inflation “number” upset daily share pricing response
35 companies, 1 interpreter!
Insight, foresight and recommendation
Bellicum Pharmaceuticals (BCLM) - January '18 opened at $9.23, slipping to a low of $6.80 on 1/31 flowed by 2/1's $5.87 yet jumping to $6.60 by 2/16. After the KITE and JUNO acquisitions, many percieve that BLCM could be percieved as an appreciator in 2018 ... We do NEED to remember; the U.S. FDA placed a clinical hold on its lead product candidate BPX-501 that's being assessed as an adjunct T-cell therapy administered after haploidentical hematopoietic stem cell transplant. The hold reportedly stems from three cases of potentially treatment-related encephalopathy (abnormal brain function) that occurred during an ongoing trial. BLCM's shares were down 1/31/18 by 33.5% on heavy volume in response to this news.
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors